Research and development areas of focus - Bristol Myers Squibb

Therapeutic areas

Oncology

Taking inspiration from our heritage of redefining standards of care in the treatment of solid tumors, our researchers continue to solve complex scientific problems on behalf of patients everywhere.

Hematology

With the delivery of many transformational firsts in hematology, we remain committed to breaking ground across a spectrum of diseases with high unmet need.

Immunology

We are working to deliver meaningful solutions that address unmet needs in dermatology, gastroenterology, pulmonology and rheumatology.

Cardiovascular

We are building on our 70-year legacy of discovering and delivering paradigm-changing medicines, leveraging our experience and expertise formed over the past several decades to take cardiovascular research to the next level.

Neuroscience

We are committed to discovering and developing medicines in neuroscience that modify disease and improve quality of life.

Drug platforms

Cell therapy

Cell therapy is a modality that leverages the natural power of cells, enhanced through genetic engineering, to selectively destroy or replace disease-causing cells.  Cell therapies can be derived from primary human cells or from pluripotent stem cells.

Targeted protein degradation

With targeted protein degradation, researchers are harnessing the cell’s own machinery to degrade disease-causing proteins that were previously considered “undruggable” and promote homeostasis.

Antibody-drug conjugates

Antibody-drug conjugates are engineered to deliver therapeutics to targeted locations. They do so by tethering therapeutic payloads (which can include protein degraders, immune stimulators, cytotoxic drugs, and oligonucleotides) via a linker to monoclonal antibodies, which act as honing mechanisms.

Biologics

Biologics are large molecules produced from living organisms that may consist of a variety of organic compounds. Examples include antibody-based medicines, traditionally referred to as monoclonal antibodies. Now researchers are also creating bi-and tri-specific monoclonal antibodies that have two or three distinct binding domains, allowing them to bind to multiple antigens simultaneously. Fusion proteins are also biologics and combine the attributes of two or more proteins into a single molecule.

Drug delivery technology

Novel technologies that will safely and effectively deliver medicines to patients via new and potentially more desirable or convenient routes of administration.

Millamolecules

Millamolecules are mid-range compounds that fall in size between small molecules and biologics. Size is not the only consideration for this class, as millamolecules should also be orally available and able to interrupt protein-protein interactions.